Vaxcyte (PCVX) news
Recent news
VaxCyte closes $1.15B offerings of stock, warrants, notes
Vaxcyte, Inc. (NASDAQ: PCVX) has completed two public offerings, raising a total of $1.15 billion in capital. The clinical-stage vaccine developer announced the successful execution of a $500 million underwritten sale of common stock and pre-funded warrants, alongside a $500 million offering of…
AInvest Wire · 6d agoVaxcyte closes $1.15B offerings of stock, warrants, notes
Vaxcyte, Inc. (Nasdaq: PCVX) has completed a $1.15 billion capital-raising initiative, comprising $500 million in common stock and pre-funded warrants and $500 million in convertible senior notes due 2032, with an additional $150 million in over-allotment options exercised by underwriters. The…
AInvest Wire · 6d agoVaxcyte said to allocate no shares to half of orders placed
AInvest Wire · Oct 7, 2026Vaxcyte prices public offering at $64.00/shr
Vaxcyte Inc. (NASDAQ: PCVX) has priced a public offering of common stock at $64.00 per share, according to recent disclosures. The offering, which includes 11 million shares, is expected to generate gross proceeds of approximately $694 million before expenses and underwriting discounts. The company…
AInvest Wire · Oct 7, 2026Vaxcyte shares fall 2.4% after co commences public offering of stock, warrants and convertible notes
AInvest Wire · Oct 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.